Similar articles

• The use of immunotherapy to enhance tumor rejection immunity in leukemic (L2C) guinea pigs following remission induction with MeCCNU.

  Klein DL, Cote P, Garner W, Wallen RM, Pearson JW. Klein DL, et al. Leuk Res. 1980;4(1):185-95. doi: 10.1016/0145-2126(80)90059-4. Leuk Res. 1980. PMID: 7412356 No abstract available.
• [BCG and experimental leukemia].

  Amiel JL, Berardet M. Amiel JL, et al. Ann Inst Pasteur (Paris). 1972 Apr;122(4):701-14. Ann Inst Pasteur (Paris). 1972. PMID: 4559236 French. No abstract available.
• Antitumor activity of cell-wall skeleton of Propionibacterium acnes C7 in mice and guinea pigs.

  Azuma I, Yamawaki M, Yoshimoto T, Saiki I, Uemiya M, Tanio Y, Tokuzen R, Yasumoto K, Yamamura Y. Azuma I, et al. Gan. 1979 Dec;70(6):737-48. Gan. 1979. PMID: 395008
• Immunological studies of the guinea pig L2C leukemia.

  Green I, Forni G, Konen T, Hu CP, Schwartz BD, Kask A, Shevach EM. Green I, et al. Fed Proc. 1977 Aug;36(9):2264-7. Fed Proc. 1977. PMID: 328308 Review. No abstract available.
• Immunotherapy of human leukemia.

  Baker MA, Taub RN. Baker MA, et al. Mt Sinai J Med. 1972 Nov-Dec;39(6):548-65. Mt Sinai J Med. 1972. PMID: 4565179 Review. No abstract available.